Home / Transcripts / Electromed, Inc. (ELMD) · November 12, 2025

Electromed, Inc. (ELMD) Earnings Call Transcript

November 12, 2025

NYSE American US Health Care Health Care Equipment and Supplies earnings 28 min

Earnings Call Speaker Segments

Mike Cavanaugh executive
#1

Good afternoon, everyone, and thanks for being on Electromed's earnings call. Electromed, Inc. put out its financial results for 2026Q1 earlier today. You can find that press release right now on the company's website, www.smartvest.com. Before we begin, I want to remind all of you that certain statements management makes during this call count as forward-looking statements, which includes remarks regarding the company's future operating and financial results and plans. Risks and uncertainties apply to such statements, and those could lead actual performance or achievements to differ materially from what has been projected. Statements of this kind reflect management's expectations only as of today's date. Undue reliance should not be placed on those forward-looking statements, and no obligation is undertaken by the company to update or revise forward-looking statements, whether from new information, future events, or otherwise. For further guidance on this matter, please refer to the company's SEC filings. With me on the call today are Jim Cunniff, Electromed's President and Chief Executive Officer, and Brad Nagel, Chief Financial Officer. Just like on previous calls, Jim will give operational highlights from the quarter, then Brad will go over the financials, and we will wrap up with a question and answer session. With that, I'll hand the call over to Jim Cunniff, President and Chief Executive Officer of Electromed.

Jim Cunniff executive
#2

Thanks, Mike, and I appreciate all of you for being on the call. It's a pleasure to report that the fiscal year opened with considerable momentum, marking our 12th straight quarter in which both revenue and profit rose compared with the same period a year earlier. That steadiness speaks to the durability of our underlying business, the commitment shown by our people, and widening appreciation of our SmartVest therapy as an essential component in treating bronchiectasis patients effectively — a chronic illness for which no cure exists. Beyond that, I'm delighted to say Time Magazine has included us in its first-ever list of America's top 100 growth leaders. That ranking gathers the highest-achieving publicly traded US companies, chosen for both revenue growth and financial strength. Being counted among this select group, drawn from a broad spectrum of industries, makes us proud. Turning to our Q1 key financials, revenue came in at $16.9 million, up 15% versus a year ago. I'm glad to say the increase was spread widely across all three of our main channels. Our primary home care channel posted 13% growth compared with last year, driven by steady gains in sales force productivity and our ongoing deliberate buildup of the sales team. Distributor sales climbed 41%, helped by sustained demand from the home medical equipment partners we've carefully selected. Hospital sales jumped 52%, highlighting early returns from the strategic investments we've made in this developing channel. We've recognized for a long time that hospitals serve as a vital intervention point for those suffering from chronic respiratory conditions, especially bronchiectasis. It's in hospitals that many such patients first show symptoms, and it's there that early diagnosis and treatment choices get made. Because of that, we'll keep putting resources into this market. Operating income climbed to $2.7 million, a 38% year-over-year gain, equal to 16% of revenue. That's a solid sign of our operating efficiency and cost discipline, which assisted in generating Electromed's operating leverage. The power throughout our P&L let us produce fully diluted EPS of $0.25, a major gain relative to the previous year. As we said earlier in fiscal 2026Q1, our Board approved a stock repurchase program worth $10 million. That underscores our conviction that Electromed stays a compelling investment and carries forward our pledge to give value back to shareholders. Against that strong top-line growth, I'd like to cover a few of our continuing commercial efforts that helped produce these solid results. Just as in earlier quarters, we keep investing in our commercial infrastructure to underpin long-term growth. During fiscal 2026Q1, we grew our direct home care sales force to 57 representatives, compared with 55 in Q4 of fiscal year 2025. This is the group that will keep positioning Electromed as the home care market leader. As we've noted on prior calls, one of the most compelling opportunities for Electromed involves serving the sizable, underserved market for bronchiectasis treatment. Currently, an estimated 923,000 patients across the United States have a bronchiectasis diagnosis, but just 6% are receiving high-frequency chest wall oscillation therapy. So what we're looking at right away is a group of close to 800,000 patients with a diagnosis who, in our view, stand to gain from using SmartVest. What's even more striking is the estimate that another 4 million-plus people may have bronchiectasis that hasn't been diagnosed yet, which really underscores how urgently education is needed. To help close that gap, we introduced the Triple Down on Bronchiectasis campaign, and it pushes a treatment approach built on three pillars. First, get the airways cleared right away using SmartVest to clear out mucus. Second, address the patient's infection. Third, assist in bringing down inflammation. This idea of stressing airway clearance as the first step is something that's landing well with doctors and patients alike. That message has gotten out to more than 18,000 people, and over 3,000 of them have gone a step further and interacted with what we've published. We're also putting continued money into clinical education and advocacy aimed at supporting earlier diagnosis and proper prescribing of SmartVest therapy; during fiscal 2026Q1, we put on three CEU webinars for healthcare professionals — two of them covering the ABCs of bronchiectasis and a third on bronchiectasis overlap syndromes. On top of that, this quarter we'll be present at three national trade shows plus a large number of regional events, where we'll display our technology and drive home how much airway clearance matters in managing bronchiectasis. As another illustration, we finished a manuscript drawing on data from the NTM bronchiectasis research registry, and it showed that despite meeting clinical criteria, 58% of qualifying patients had not been prescribed H therapy. That shortfall is a real opening for earlier intervention, and our team is focused on closing it. From an operational standpoint, Q1 was a landmark quarter. We got a new CRM system up and running on schedule and within budget, and it caused zero interruption to what our sales team does. Already, this platform is boosting productivity in the field, giving us sharper market insights, and improving how we coordinate with our fulfillment teams. On earlier calls, I've told you about our Smart Order e-prescribe solution for prescribers, which does away with the old fax-based way of doing things. This shift makes our clinics far more efficient, because it hands Electromed complete prescription documentation without any friction, letting us get SmartVest out to patients faster so they can breathe easier. During Q1, more than a third of our orders came in electronically, which means quicker fulfillment and better results for patients; we also wrapped up the manufacturing optimization plan we started in fiscal 2025, and our operations team carried it out without a single flaw. One part of that effort was physically reconfiguring our manufacturing facility, all with an eye toward making production more efficient. Even with how complicated that transition was, patient deliveries never got disrupted. And while we're on the subject of manufacturing, I want to stress that Electromed is a company based in the US, with our operations and product assembly taking place in the US; and 99% of our net revenues come from the US. Because our business operations are so concentrated in the US, we believe we're in a strong position to keep up our solid record of delivering to customers on time and to hold our gross margins at the mid-seventies or better; that said, we're keeping a close watch for any problems from our mostly domestic suppliers, who could face tariff exposure further up their supply chains. All in all, I couldn't be happier with how the Electromed team has performed, and I anticipate that carrying on through fiscal 2026 and past it. That wraps up what I had ready to say, so at this point I want to hand things over to Brad so he can walk us through the financials. Brad?

Brad Nagel executive
#3

Appreciate that, Jim. Every figure I give relates to the three months that closed on 09/30/2025 — our first quarter of fiscal 2026 — and is being measured against the three months that closed on 09/30/2024, which was Q1 of fiscal 2025. Net revenues climbed 15.1%, reaching $16.9 million, versus $14.7 million previously. Within our direct home care operation, revenue rose 12.7% year over year, hitting $14.9 million, compared with $13.2 million. That top-line improvement came mainly from having more direct sales representatives as well as greater net revenues generated by each sales rep. During Q1, our average headcount of home care sales reps was 57, spread across 61 territories, and those reps produced an average annualized home care revenue of $1,052,000 in Q1, which sits inside Electromed's goal band of $1 million to $1.1 million. Revenue from our businesses outside home care also rose year over year, landing at $2 million. Home care distributor revenue came to $829,000, a gain of 41.2%. Hospital revenue jumped 51.7%, rising to $1,047,000; those gains were partly offset by other revenue falling 32.2%, down to $122,000. Gross profit rose to $13.2 million, equaling 78.1% of net revenues, compared with $11.5 million, or 78.3% of net revenues. The larger gross profit dollar figure stemmed mainly from greater overall revenue and more net revenues per device. The lower gross profit percentage came about because of higher costs, which were partly offset by more net revenues per device. Selling, general, and administrative expenses totaled $10.3 million, which was up $900,000, or 9.6%. This period's rise was chiefly attributable to greater salaries and incentive compensation tied to a larger average headcount in the sales, sales support, marketing, and reimbursement teams needed to handle a higher volume of patient referrals. Operating income came in at $2.7 million, or 15.8% of net revenues, versus $1.9 million, or 13.2% of net revenues. That 37.8% growth in operating income resulted mainly from higher revenue and gross profit. Net income rose 44.9%, reaching $2.1 million, or $0.25 per diluted share, compared with $1.5 million, or $0.16 per diluted share, in the first quarter of the previous fiscal year. At 09/30/2025, Electromed held $14.1 million in cash along with $24.8 million in accounts receivable and carried no debt, delivering working capital of $35.8 million and total shareholders' equity of $44.7 million. The cash balance represents a $1.2 million decline for Q1 of fiscal 2026. That quarterly cash reduction was driven mainly by repurchasing $1 million worth of Electromed common stock. To wrap up, we're pleased with this strong financial beginning to the fiscal year and keep seeing chances to fulfill our goals of double-digit top-line growth and greater operating leverage in fiscal year 2026. With that said, we'd like to turn to the Q&A part of the call. Operator, please open the line for questions.

Kyle Bauser analyst
#4

Excellent. Thank you. Hi, Jim and Brad. Once again, strong results. I appreciate you fielding my question. Perhaps I'll begin with Jim — you noted that 55% of eligible patients have received a VEST prescription so far. Clearly, that represents a sizable opportunity. Is that reflected in your growth trajectory? So, how much of your expansion stems from better awareness and new users, as opposed to prescribers you already had?

Jim Cunniff executive
#5

Excellent question, Kyle — I appreciate you posing it, and I hope you're doing well. Our view is that bringing on additional sales representatives, something we've done fairly steadily year over year, forms part of what makes us unique. We remain firmly of the belief that this is predominantly a clinical sale. That said, I believe now is a fantastic moment and setting for bronchiectasis. Over the past quarter — our fiscal 2026Q2 — as I noted during my prepared remarks, we've been present at numerous trade shows. We're beginning to observe growing numbers of people, physicians included, taking to podiums to discuss bronchiectasis treatment paradigms; there's a new market participant, as you're aware, on the pharmaceutical side, that has spent considerable sums on market awareness, for patients and physicians alike, which genuinely amplifies our own efforts. And so, I believe awareness is simply tremendous right now. I think we're benefiting from some tailwinds because of that. Yet I also believe we keep capturing additional market share as a single product company devoted to this space.

Kyle Bauser analyst
#6

Understood. Understood. And from what we've seen in our checks, there appears to be a fairly meaningful opening when it comes to treating people at an earlier stage, you know, as the disease advances. I believe one physician said that often, many patients end up finally receiving treatment only after the house has essentially burned to the ground, which is roughly what you hinted at in your remarks. Naturally, treating sooner depends on reimbursement and indications for use and, obviously, on raising awareness, and perhaps market development efforts are quite cost prohibitive when you're trying to treat earlier. But I suppose, do you see routes toward treating a wider patient population, you know, from a reimbursement angle, you know, without needing to do a scan, and so on? It simply appears that, you know, patients might gain from this before they sort of crash.

Jim Cunniff executive
#7

Oh, no. We completely agree with you. I think that's a piece of the education campaign. And, you know, one item I brought up in my prepared remarks was the manuscript that we're hoping to get published. And yeah, the shameful part is that, you know, when we examined the NTM registry data, you know, 58% of the patients qualified; so everything you just listed, you know, having a CT scan, having a daily productive cough for six months, and, you know, having tried and failed something, they qualified for that, and still they weren't started on the HFCWO therapy earlier. And so we believe that manuscript and, you know, building more awareness around clearing the airways sooner and the fact that many of these patients already meet reimbursement guidelines, I think, will be a real benefit. I don't think the reimbursement criteria for HFC, whether it's our device or anyone else's, is going to change. I just think that the prescribing physicians are going to be far more open to putting patients on the therapy sooner rather than later. I think that's a big benefit, not only to the patients but also to the space in general.

Kyle Bauser analyst
#8

Absolutely. Yes, I concur. And in that presentation, I believe you highlight that neuromuscular accounts for 22% of home care qualified referral volume. Is there anything worth mentioning regarding further chances to grow?

Jim Cunniff executive
#9

Oh, absolutely. What I mean is, Kyle, at present there are many ICD-10 codes for which reimbursement for HFCWO will, you know, be available. What makes it difficult is that the reimbursement guidelines lack the clarity they possess for bronchiectasis. And, as I've said repeatedly, this enormous unmet need persists. Essentially, 800,000 patients nationwide today suffer from the disease, have received a diagnosis, yet they are not undergoing, you know, SmartVest therapy. So we aim to unlock that market opportunity; and that figure doesn't even account for the further 4.1 million individuals with bronchiectasis COPD overlap who remain undiagnosed. Thus I believe if we can unlock that iceberg of opportunity, we will seize it; that applies solely to the bronchiectasis space. Yet there are other conditions, you know, such as cystic fibrosis, and neuromuscular diseases, you know, where patients can gain from this technology. Therefore, as we shift into calendar year '26, one action we will take with our sales reps is to have them really focus intensely on some of those more prevalent disease states where, you know, we can obtain reimbursement for the technology.

Kyle Bauser analyst
#10

All right, got it. Maybe just one last item. It's really encouraging to see how strongly the hospital channel is doing. Do you have specific reps whose sole focus is hospitals, or is it your direct sales force and maybe distributors who go after that channel? I'm just curious.

Jim Cunniff executive
#11

Yes. No. That's a great question. As you know, we don't depend on distributors to go after that channel for us. Our strategy is largely direct to patient. And with respect to hospitals, for about the last 2 years, we've been very deliberate about investing in that space. Our thinking is that this acts as a gateway for getting patients onto the technology while they're in the hospital, as I mentioned in my prepared remarks. Then, after they're discharged, our aim is for them to be using our technology at home. So right now we have 3 sales reps focused on that channel. We plan to add reps there in a disciplined manner. Yes. The sales cycle in the hospital market is very different from the home market. In the home market, it's a capitated rental model. It's pretty simple. Not simple, but when our sales reps go to a clinic and talk with the physician, they can work together with that physician to identify patients who might benefit from our technology. With hospitals, it's really a capital sale. As a result, the time to revenue can at times extend to years, depending on how the facility's buying cycle works. So we're seeing a lot of interest as hospitals refresh their fleets and as their capital budgets permit them to buy high-frequency chest wall oscillation devices. We also have a contract with Visient, which covers half the health systems nationwide. Given some of the current market dynamics, plus the fact that we have a best-in-class technology that we believe would help hospitals and their staff since it's so intuitive to operate, we feel we're in a very strong position. And the patients we'd place on the product. Revenue in our non-home care businesses increased year-over-year, coming in at $2.0 million.

Kyle Bauser analyst
#12

All right. Thanks. Impressive numbers. I'll get back in line.

Jim Cunniff executive
#13

Excellent. Appreciate it, Kyle.

Ben Haynor analyst
#14

Good afternoon, everyone. I appreciate you taking my questions. To start, I want to follow up on the hospital topic we were just discussing. Given that sales cycles run longer in that space, it stands to reason you'd have a decent handle on the opportunities in your pipeline. So how strong is your visibility into that? And should those watching the stock treat roughly a million dollars per quarter as a fresh standard for that part of the company?

Jim Cunniff executive
#15

Thanks, that's a terrific question, and we're glad you joined the call. From where we sit, Ben, this is exactly why we aren't concentrating everything in one place. Home care remains the core area of emphasis for us as an organization, which means reaching out to clinics and to the pulmonologists working in them. Our view is that this opportunity is still largely untapped. The hospital side of things tends to be somewhat erratic, since you're essentially subject to the budgeting decisions hospitals make. You're also subject to the choices of standardization committees. There are simply many more people involved in those calls. We do believe that by directing attention there, and by doing so in places where we see fleets getting refreshed or organizations purchasing new equipment, yes, we ought to keep delivering at minimum 20% plus expansion in that segment. The way it unfolds is somewhat harder to forecast. Still, we believe that once things shake out across the year, for the fiscal year, that market should expand at a pace well above whatever growth our home care operation posts, even though it sits on a very small base.

Ben Haynor analyst
#16

Understood. So simply being present in that space means there's a solid likelihood that business will come your way.

Jim Cunniff executive
#17

Correct. Our view is that we possess an excellent offering, and we intend to reach the whole market using just a handful of personnel. Yet that also builds a great deal of insight for us as we prepare to grow within that segment. In much the same way we handle our home reps, we simply don't — we've watched businesses pour lots of resources into a possibility only for nothing to come of it, after which they must pull back. The strategy we've chosen strikes us as the correct one. However, if we observe the algorithm allowing us to bring on additional reps earlier instead of later, we will definitely be doing so.

Ben Haynor analyst
#18

Understood. Now, regarding that new pharmaceutical alternative, we've already touched on it somewhat here. How do you expect clinicians' approach to treatment protocols to shift as they try to get patients onto that medication, and clearly, once the infection is resolved, bring a greater number of individuals over to your device?

Jim Cunniff executive
#19

Ben, that's an excellent question. Look, they've generated substantial awareness around bronchiectasis, which has been wonderful. What this drug does not accomplish, however, is clearing mucus. That's precisely where our role begins. As I noted regarding our Triple Down on Bronchiectasis campaign, above all else, if a patient is going to breathe more easily, that mucus must be removed, since it serves as the fuel for a subsequent infection. Bronchiectasis is already present in these individuals. It's chronic. It's irreversible. So as mucus accumulates inside their airways, our goal is to eliminate it. If an infection does occur, the current standard involves antibiotic treatment, after which the drug's purpose is essentially to reduce future inflammation. Curing the disease is not something it does, though. That's why we view it as complementary to our offering. As for prescribing patterns, my sense is that physicians who prescribe are enthusiastic about it. When they have a patient experiencing frequent exacerbations, perhaps they'll consider prescribing this. Some, I believe, remain on the sidelines, essentially adopting a wait-and-see posture. The other difficulty with this drug, I'd say, is that it's a costly proposition, from the payer perspective as well. It runs $85,000 per patient per year. Our technology, by contrast, comes to over $10,000 for life. Right? And these individuals are living with a chronic illness. So relative to the drug, it's early innings, but a great deal of awareness has been created by them. And thus far, reimbursement has not come their way from either CMS or commercial payers. So we'll see.

Ben Haynor analyst
#20

Perhaps the best way to frame this is that the drug works like a set of very costly snow tires, yet there are still additional factors you must keep in mind while driving through snow.

Jim Cunniff executive
#21

That comparison is quite apt.

Ben Haynor analyst
#22

Ben Haynor from the local Minnesota area. There we are.

Jim Cunniff executive
#23

Jim Cunniff here — I believe that covers everything on my end. Appreciate you fellows for fielding the questions.

Ben Haynor analyst
#24

Hi there. Good to meet you. Appreciate your participation on this call. Thanks.

Jim Cunniff executive
#25

Well, thanks to everyone for dialing in today. I believe you ought to feel good about the way Electromed is truly carrying things out with precision throughout every part of our operations. Our revenues and profits are rising, our commercial footprint is getting bigger, and we're putting money into strategic efforts that set us up for success over the long term; and I brought up a few of those during today's call, among them the manufacturing optimization program we recently wrapped up. We've additionally rolled out a new CRM system, something we're quite enthusiastic about. And we stay dedicated to providing value for our patients, providers, and shareholders, and we're eager about what's coming down the road; so thanks to each of you, and I appreciate your presence on this call.

Operator operator
#26

That brings us to the end of this call. We appreciate your joining us for today's presentation. You're welcome to disconnect at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Electromed, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Electromed, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.